Breathomix, developed a technology, BreathBase, that analyzes the complete mixture of molecules within exhaled breath and returns a diagnostic answer within seconds in the doctor’s office. The data allows doctors to diagnose and subtype lung disease, such as asthma, COPD and lung cancer. BreathBase analyzes patient’s exhaled breath in real-time based on advanced signal processing and an extensive online reference database, infused with AI.
Diagnosing pulmonary diseases is often difficult and time-consuming. Treatment strategies are mostly based on trial and error which leads to increased mortality and hospitalization rates, unnecessary loss of patients’ quality of life, wasted time and insurer money. Now it is possible for patients to receive the right treatment during their first visit to the doctor. With the data instantly at their fingertips, physicians can provide on the spot care using BreathBase. Beyond that, AI can provide insights that are predictive in nature, identifying individuals who are likely to respond to a specific treatment or maybe will develop a specific lung disease in the near future, helping doctors provide the best treatment.
The Dutch startup has an agreement with CBusineZ, a foundation related to CZ insurance company in Netherlands. Together with CBusineZ they push the technology to the market through selected clinical partners.
Immediate results with >90% accuracy
Breathomix has developed BreathBase for the early detection of lung cancer, to identify chronic airway disease such as asthma and COPD and to predict response to therapy. The solution has broad applications and has a solid value proposition towards physicians, general practitioners and health insurers. BreathBase is the first non-invasive, easy to use and cheap diagnostic tool available that provides immediate results with >90% accuracy in the doctor’s office. On top of that it is the only on-line solution in the field, which makes the technology easily scalable, and more so than any other system.
Performed studies with the BreathBase solution range from extensive technical validation studies, pilot studies and prospective observational studies. Together with 10 centers across the Netherlands and key centers in Sweden and Canada they performed a large multicenter study in which they included >3.000 patients with chronic airway disease and/or lung cancer. They are now taking the final step towards implementation; treating new patients, with their consent, based on the BreathBase results in a real-world setting.
How it works
- Step 1: The patient takes a deep breath and slowly exhales through the SpiroNose. The 7 different sensors in the SpiroNose capture the complete mixture of molecules in the patient’s exhaled breath.
- Step 2: The sensor signals are directly sent to and stored on the online BreathBase server.
- Step 3: BreathBase analyses the sensor signals in real-time based on advanced signal processing and an extensive online reference database, infused with AI.
- Step 4: The obtained breath profiles, “Breathprints”, are compared to the online reference database and based on machine learning algorithms a final diagnostic and/or phenotypic answer will be established.
Why we selected Breathomix for DIA Amsterdam
Similar to blood and urine, exhaled breath contains thousands of biomarkers that can be used for diagnosis, phenotyping and prediction of response to therapy. The BreathBase is the only exhaled breath technology that is non-invasive and provides on the spot information that help physicians diagnose patients at early stage, phenotype and select treatment strategies during patient consultation. The solution has applications throughout the full health care sector and has a solid value proposition towards physicians, general practitioners and health insurers. BreathBase is the first non-invasive, easy to use and cheap diagnostic tool available that provides immediate results with >90% accuracy in the doctor’s office. On top of that it is the only online solution in the field, which makes the technology scalable.
At DIA Amsterdam Maurik van de Heuvel (CEO) & Rianne de Vries (COO) from Breathomix will present an introduction of exhaled breath analysis, early diagnosis of lung cancer and prediction of response to immunotherapy, resulting in significant cost reduction, a demo and future plans and applications.
Who is Breathomix?
Breathomix consists of a team with over 20 years of combined experience in the field of exhaled breath analysis, cloud applications, machine learning and big data analysis. The company is founded by Rianne de Vries (COO) and Maurik van den Heuvel (CEO) in 2018. Rianne is the founder of the BreathBase platform that automatically processes and analyzes the exhaled breath in order to diagnose and phenotype disease or to predict response to treatment. Maurik brings the experience and the people needed to implement the cutting-edge technology that helps make BreathBase scalable, secure and successful. Breathomix cooperates with carefully selected third parties, including Microsoft HQ and Tecknoworks Europe in terms of software development, architecture and hosting and Evalan for the hardware development.
“We want to be the most impactful provider of Artificial Intelligence for healthcare in the world. We want to make serious impact, on healthcare itself, and on people’s lives.” Maurik van den Heuvel, CEO Breathomix
“We envision that in the near future breath analysis will become as common as having your blood tested” Rianne de Vries, COO Breathomix and founder of BreathBase